CCR4 and head and neck squamous cell carcinoma: In a completed phase 2 study with CPI‐experienced R/M HNSCC, FLX475a selective CCR4 antagonist in combination with pembrolizumab was shown to be well tolerated and has good efficacy particularly in those with HPV‐positive tumors.191